GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults

This article was originally published on ContagionLive®.

GSK has announced promising results for Arexvy, its respiratory syncytial virus (RSV) vaccine, showing a cumulative efficacy of 62.9% against RSV-related lower respiratory tract disease (RSV-LRTD) over 3 full RSV seasons in adults aged 60 years and older. This vaccine is the only one with efficacy and safety data available through 3 full seasons, including in individuals at increased risk due to underlying medical conditions.¹

The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus-related lower respiratory tract disease in older adults over 3 seasons. | Image credit: MargJohnsonVA - stock.adobe.com

The findings were presented at the CHEST 2024 Annual Meeting, indicating 67.4% efficacy against severe RSV-LRTD. In the third season, the vaccine's efficacy was 48% against RSV-LRTD (95% CI, 8.7-72). The safety profile is consistent with previous phase 3 results, where the most frequently reported side effects included injection site pain, fatigue, myalgia, headache, and arthralgia within four days of vaccination.

GSK plans to continue providing long-term efficacy and immune response data to help inform revaccination schedules. RSV impacts an estimated 64 million people globally each year and can lead to severe outcomes, causing over 465,000 hospitalizations and 33,000 deaths annually among adults aged 60 and older in high-income countries.

“We are excited by these new data which show that a single dose of Arexvy could help protect millions of older adults at risk of RSV disease over three seasons to benefit public health," Tony Wood, chief scientific officer at GSK, said in a statement. "This is the only RSV vaccine with efficacy and safety data available through 3 full seasons. We will continue to provide data on longer term follow-up to help recommending bodies determine future revaccination schedules.”

Arexvy was approved by the FDA in May 2023 for preventing RSV-LRTD in individuals aged 60 and older. Since then, it has received approvals in 50 countries, including Europe and Japan. This approval was based on the US phase 3 trial data that showed 82.6% efficacy against RSV related lower respiratory tract disease and 94.6% efficacy in patients with comorbidities. Arexvy combines the preF fusion protein with the AS01 adjuvant to enhance immune response in aging populations.²

The ongoing research aims to provide further insights into the vaccine's long-term effectiveness and the necessity for potential revaccination.

References

1. GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons. GSK. October 8, 2024. Accessed October 21, 2024. https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-arexvy-its-rsv-vaccine-indicating-protection-over-three-rsv-seasons/
2. Cosdon, N. FDA approves GSK’s Arexvy as the world’s first RSV vaccine for older adults. Contagion. May 3, 2024. Accessed October 21, 2024. https://www.contagionlive.com/view/fda-approves-gsk-s-arexvy-as-the-world-s-first-rsv-vaccine-for-older-adults